Core Insights - Johnson & Johnson (JNJ) has submitted a type II variation application to the European Medicines Agency (EMA) for the expanded use of Tecvayli (teclistamab) as a monotherapy for adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy [1][9] Regulatory Developments - The application is supported by data from the ongoing phase III MajesTEC-9 study, which demonstrated that Tecvayli significantly improved outcomes compared to standard-of-care regimens, showing a 71% reduction in the risk of disease progression or death and a 40% reduction in the risk of death [5][6] - Tecvayli is currently approved in Europe for patients with RRMM who have received at least three prior therapies [2][10] Financial Performance - JNJ reported global sales of Tecvayli at $670 million in 2025, reflecting a 22% year-over-year increase, driven by expansion into community settings [9][12] - Over the past year, JNJ's shares have increased by 49.6%, outperforming the industry growth of 14.3% [4]

Core Insights - The article discusses the potential market challenges ahead, emphasizing the importance of investing in safe Dividend Aristocrats amid rising geopolitical tensions and economic uncertainties [1][2] - It highlights the characteristics of Dividend Aristocrats, which are companies that have consistently increased dividends for at least 25 years, making them attractive for long-term investors seeking stability [1][2] Summary by Company Abbott Laboratories - Abbott Laboratories announced a 6.8% dividend increase in December, marking its 54th consecutive year of dividend growth, with a total increase of over 70% since 2020, currently yielding 2.10% [1] - The company operates in various segments, including Medical Devices, Nutritional Products, Diagnostic Products, and Established Pharmaceutical Products [1] Automatic Data Processing (ADP) - ADP is a leader in payroll and HR services, providing cloud-based solutions to over 80% of Fortune 100 companies, with a current dividend yield of 2.94% [1] - The company serves a diverse client base, offering a range of human capital management solutions, including payroll services and compliance services [1] Coca-Cola - Coca-Cola pays a reliable 2.50% dividend and has seen organic revenue growth of 5% in 2025, with expectations of 4% to 5% growth in 2026 [2] - The company offers over 500 brands and is the world's largest beverage company, with a significant market presence in sparkling beverages and ready-to-drink products [2] Johnson & Johnson - Johnson & Johnson, trading at 14.5 times forward earnings, offers a 2.07% dividend and is recognized for its diversified healthcare product portfolio [2] - The company operates in two main segments: MedTech and Innovative Medicine, focusing on various therapeutic areas [2] NextEra Energy - NextEra Energy raised its quarterly dividend by 10% and has committed to 10% annual dividend growth through this year, with a current yield of 2.44% [2] - The company operates through subsidiaries focused on electric power and energy infrastructure, including Florida Power & Light and NextEra Energy Resources [2]

Core Insights - Johnson & Johnson is experiencing exciting developments in its surgery division, particularly with the advancement of its robotic surgical system [2] Company Developments - The company is nearing the final stages of bringing its robotic surgical system to market after a long and complex development process [2]

Key Takeaways J&J won EU approval to expand Akeega use to BRCA1/2-mutated metastatic hormone-sensitive prostate cancer.JNJ's phase III AMPLITUDE study showed the combo nearly halved the risk of disease progression or death.Akeega was approved in the EU in 2023 for BRCA-mutated metastatic castration-resistant prostate cancer.J&J (JNJ) announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. T ...

Johnson & Johnson (NYSE:JNJ) FY Conference March 10, 2026 11:30 AM ET Company ParticipantsHani Abouhalka - Group Chairman of SurgeryConference Call ParticipantsMatt Miksic - Equity Research AnalystMatt MiksicStill morning. Good morning, everybody. Very happy to have with us this year from J&J, Hani Abouhalka, Group Chairman of Surgery, otherwise known as the man behind the robot. My name is Matt Miksic. I cover MedTech here at Barclays. You know, exciting times at Johnson & Johnson in surgery. After a bunch ...

记者丨韩利明 编辑丨季媛媛 骆一帆 随着跨国药企陆续披露2025年业绩报告，全球制药行业的新一轮竞争格局逐步清晰。 业绩榜单中，强生以全球941.93亿美元的总营收斩获榜首，旗下创新制药和医疗科技两大核心 业务板块分别收入604.01亿美元（+6%）和337.92亿美元（+6.1%）；礼来凭借44%的高增 速，实现651.79亿美元的全年营收，成为增速最快的头部药企。此外，赛诺菲、诺华、阿斯利 康、艾伯维等头部企业营收均保持上升趋势，共同支撑全球制药行业稳步发展。 | | | | | 2025年营收前十跨国药企财务数据(单位:亿美元) | | | | --- | --- | --- | --- | --- | --- | --- | | 排名 | 公司 | 全球总营收 | 同比增速 | 中国区营收 | 同比增速 | 备注 | | 1 | 强生 | 941.93 | 6% | | | | | 2 | 罗氏 | 744. 28 | 7% | 36. 71 | 10% | 全球营收615. 16亿瑞士法郎:中国 区制药业务营收30.34亿瑞士法 郎,按1瑞士法郎=1. 2099美元换算 | | 3 | 礼来 | 6 ...

Core Insights - Johnson & Johnson (NYSE: JNJ) is involved in a $65 million antitrust class action settlement related to its pulmonary hypertension drug Tracleer, which allegedly delayed competition for a generic version of the medication [2] - The company operates through two main segments: Innovative Medicine, focusing on therapeutic areas such as oncology and immunology, and MedTech, which includes a wide range of medical devices [3] Group 1 - Johnson & Johnson units have agreed to pay $65 million to settle claims from health plans alleging overcharging for Tracleer [2] - The lawsuit claimed that Johnson & Johnson obstructed competitor access to Tracleer samples, hindering the market entry of generic alternatives [2] - Actelion Pharmaceuticals, which developed Tracleer and was acquired by Johnson & Johnson in 2017, reportedly made billions in profits from the drug [2] Group 2 - The Innovative Medicine segment of Johnson & Johnson focuses on various therapeutic areas, including oncology, infectious diseases, and cardiovascular diseases [3] - The MedTech segment encompasses a diverse range of medical devices used in fields such as cardiovascular intervention and orthopedics [3]

Core Insights - Dave Ramsey has established a prominent personal finance brand in America, emphasizing the importance of a curated reading list that has influenced his approach to money, leadership, and life [1][2] Recommended Books - **How to Win Friends and Influence People by Dale Carnegie**: This book is deemed the most important by Ramsey, highlighting that effective communication and relationship-building are crucial for success [3] - **The Millionaire Next Door by Thomas Stanley and William Danko**: This book provides statistical insights into self-made millionaires, revealing that true wealth often comes from modest living rather than ostentatious displays [4][5] - **The 7 Habits of Highly Effective People by Stephen R. Covey**: Covey's principles, particularly proactive decision-making and long-term vision, are integral to Ramsey's philosophy on wealth building [6] - **The Richest Man in Babylon by George S. Clason**: This book simplifies financial principles that have stood the test of time, emphasizing the importance of saving and investing [7] - **Good to Great by Jim Collins**: This work has influenced Ramsey's business strategies, focusing on the Hedgehog Concept, which identifies the intersection of passion, expertise, and economic drivers [8][9] - **The E-Myth Revisited by Michael E. Gerber**: Gerber's insights on why small businesses fail stress the importance of building systems rather than relying solely on individual talent [10][11] - **The 21 Irrefutable Laws of Leadership by John C. Maxwell**: This book underscores the necessity of leadership development for organizational growth, aligning with Ramsey's views on financial investment in leadership [12] - **The Go-Getter by Peter B. Kyne**: This story exemplifies the entrepreneurial spirit and resilience that Ramsey values in his team [13][14] - **Who Moved My Cheese? by Spencer Johnson**: This parable addresses adaptability in the face of change, a critical mindset for financial success [15][16] - **Boundaries by Dr. Henry Cloud and Dr. John Townsend**: This book discusses the importance of setting personal boundaries to maintain financial health, linking emotional well-being with financial discipline [17][18] Conclusion - Ramsey's reading list is grounded in timeless principles of behavior, leadership, and financial discipline, offering practical guidance for those seeking to improve their financial situation and overall life [19]

Johnson & Johnson (NYSE:JNJ) is one of the best stocks that will always grow. Johnson & Johnson (NYSE:JNJ) announced on March 5 that the U.S. Food and Drug Administration (FDA) granted approval for TECVAYLI® plus DARZALEX FASPRO® for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Management reported that the approval offers a potential new standard of care as early ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...